Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | UGCG | Q16739 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6139932 | 1.00 | MAPT (0.51) | MAPTCHRNA7KDM4EALDH1A1ALOX15 | |
| SCHEMBL6139968 | 0.90 | CHRNA7 (0.51) | MAPTCHRNA7ALDH1A1TDP1HTR3A | |
| SCHEMBL6139967 | 0.90 | CHRNA7 (0.51) | MAPTCHRNA7ALDH1A1TDP1HTR3A | |
| SCHEMBL6139906 | 0.89 | CHRNA7 (0.48) | CHRNA7HTR3ACHRNA3MEN1KMT2A | |
| SCHEMBL6139907 | 0.89 | CHRNA7 (0.48) | CHRNA7HTR3ACHRNA3MEN1KMT2A | |
| SCHEMBL6139915 | 0.81 | CHRNA7 (0.42) | CHRNA7HTR3ACHRNA3L3MBTL1 | |
| SCHEMBL6139582 | 0.80 | S1PR1 (0.42) | ALDH1A1MEN1KMT2A | |
| SCHEMBL6139580 | 0.80 | S1PR1 (0.42) | ALDH1A1MEN1KMT2A | |
| SCHEMBL6140096 | 0.78 | CHRNA7 (0.44) | MAPTCHRNA7ALDH1A1HTR3AMEN1 | |
| SCHEMBL6140099 | 0.78 | CHRNA7 (0.44) | MAPTCHRNA7ALDH1A1HTR3AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844337-B2 | 1,4-diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, their preparation and their application in therapeutics | SANOFI-SYNTHELABO (FR) | 2005-01-18 | — | — | US | disclosed |
| EP-1289986-B1 | 1,4-DIAZABICYCLO 3.2.2]NONANE-PHENYLISOXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SYNTHELABO (FR) | 2004-04-28 | — | — | EP | disclosed |
| US-20030114461-A1 | 1,4-Diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114461-A1 | 1,4-Diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof | CYC1, GLRA1, CBR1 | MAPT 4765/4885CHRNA7 207/4885KDM4E 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.